British Patient Capital has announced a follow-on investment into Grey Wolf Therapeutics as part of the company’s $50 million Series B financing expansion. This additional investment increases Grey Wolf’s Series B financing to $99 million, reinforcing confidence in its unique neoantigen modulation approach to engage the immune system against diseases. The Series B round was led by Intermediate Capital Group (ICG) Life Sciences, with participation from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, and Oxford Science Enterprises. British Patient Capital’s investment was made through the £425 million Future Fund: Breakthrough programme, aimed at supporting R&D-intensive UK companies. Grey Wolf, a clinical-stage biotechnology enterprise, focuses on antigen modulation therapies for oncology and autoimmunity. The fresh funds will further the evaluation of different tumor types in the EMITT1 clinical trial and the therapeutic potential in autoimmune diseases. Grey Wolf is set to present initial clinical data for its lead immuno-oncology program, GRWD5769, at the American Society of Clinical Oncology Annual Meeting.

Biotechnology, Private Equity, Pharmaceuticals,United Kingdom, Global